Choose a language and wait for the translated text.
Shots:
Lantheus has presented data from two pivotal P-III studies of TAUKLARIFY (florquinitau F-18 injection; MK-6240) PET imaging, used in adults with cognitive impairment being evaluated for Alzheimer’s disease to identify pts with neurofibrillary tangle (NFT) pathology, at CTAD 2026
Across 617 scans, all 5 independent readers in each study met the prespecified co-primary sensitivity & specificity criteria; in CE-20-01 (n=279) sensitivity was 79.9–88.5% & specificity 97.9–99.3%, while in CE-23-01 (n=338) sensitivity was 68.2–82.4% & specificity 93.5–99.4%, with high inter-reader agreement (Fleiss’ κ 0.92 & 0.86)
The tracer was generally well tolerated in a pooled analysis of 1,734 participants; the most common TEAEs (≥0.1%) were headache (0.7%), nausea (0.2%), dizziness, injection site reactions & abdominal discomfort (0.1% each)
Ref: Lantheus | Image: Lantheus | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Lantheus Reports P-III Data of TAUKLARIFY (Florquinitau F-18) PET Imaging in Early Alzheimer’s Disease appeared first on PharmaShots.